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An inverse correlation between the pro-inflammatory cyto-
kine interleukin-18 and the anti-atherogenic adipokine adi-
ponectin has been reported in the chronic pathological condi-
tions obesity, insulin resistance, coronary artery disease, and
metabolic syndrome.We investigated whether this relationship
is coincidental or has a causal basis. Here we show that interleu-
kin-18 (IL-18) suppresses adiponectin transcription, mRNA
expression, and secretion by 3T3-L1 adipocytes. IL-18 sup-
presses adiponectin promoter-reporter activity, an effect
reversed by deletion or mutation of the NFATc4 core DNA-
binding site. IL-18 induces NFATc4 phosphorylation (Ser676),
nuclear translocation, and in vivo DNA binding. IL-18 induces
ERK1/2phosphorylation andenzymeactivity, andpretreatment
with the MEK inhibitor U0126, ERK1/2 inhibitor PD98059, or
small interference RNA targeted to ERK1/2 attenuates ERK1/2
activation and NFATc4 phosphorylation. Finally, inhibition of
ERK1/2 or NFATc4 knockdown reverses IL-18-mediated adi-
ponectin suppression. In contrast to its inhibitory effects on adi-
ponectin expression, IL-18 potently stimulates PAI-1 secretion.
These data demonstrate for the first time that IL-18 selectively
suppresses adiponectin expression via ERK1/2-dependent
NFATc4 activation and suggest that the inverse relationship
observed between IL-18 and adiponectin in various chronic
pathological conditions is causally related. Thus, targeting
IL-18 expressionmay enhance adiponectin expression andmit-
igate disease progression.
Adiponectin is an anti-inflammatory cytokine secreted pri-
marily by adipocytes (1, 2). Paradoxically, the increased body fat
in obesity is associated with decreased circulating adiponectin
levels (3, 4). Secretion of the adipokines leptin andnerve growth
factor, on the other hand, are not affected, and in fact, their
systemic levels are increased by several folds by obesity (5, 6),
suggesting that obesity is specifically associated with reduced
adiponectin levels.
Adiponectin signalsmainly via adiponectin receptors 1 and 2
(7). A wide variety of cells express adiponectin receptors,
including vascular endothelial and smooth muscle cells, and
tissue macrophages. Thus, the cells that are known to play key
roles in the pathobiology of vascular disease are all targets of
adiponectin. Adiponectin inhibits endothelial cell activation by
suppressing cytokine, chemokine, and adhesion molecule
expression, and can inhibit smoothmuscle cell proliferation (8,
9). Adiponectin inhibits foam cell formation by suppressing
macrophage uptake of low density lipoprotein (10). Together,
these findings suggest that adiponectin acts as an anti-inflam-
matory and anti-atherogenic cytokine.
In contrast to adiponectin, plasma levels of the pro-inflam-
matory cytokine interleukin (IL)2-18 are increased during obe-
sity (10–12). Plasma IL-18 levels are also increased in other
chronic inflammatory conditions such as type II diabetes, cor-
onary artery disease, heart failure, and metabolic syndrome
(10–15). Importantly, plasma levels of IL-18 show a positive
correlation with intimal-medial thickening and predict future
cardiovascular events (16, 17). Thus, plasma IL-18 levels can
serve as a marker of chronic inflammation. Expression of IL-18
and its receptor has been demonstrated in human atheroscle-
rotic lesions localized predominantly to smooth muscle cells
(18). However, IL-18 affects all three major cell types involved
in the development and progression of atherosclerotic vascular
disease. IL-18 stimulates smooth muscle cell migration and
proliferation (19) and stimulates cytokine, chemokine, and
adhesion molecule expression in endothelial cells (20). IL-18
also modulates foam cell formation by stimulating scavenger
receptor and chemokine expression (21). In an animalmodel of
atherosclerosis, the IL-18/ apoE/ double-knockout mice
show fewer lesions and delayed lesion progression compared
* This workwas supported in part by the Research Service of the Department
of Veterans Affairs. The costs of publication of this article were defrayed in
part by thepayment of page charges. This articlemust therefore behereby
marked “advertisement” in accordancewith 18U.S.C. Section 1734 solely to
indicate this fact.
1 To whom correspondence should be addressed: Medicine/Cardiology,
The University of Texas Health Science Center, 7703 Floyd Curl Dr., San
Antonio, TX 78229-3900. Tel.: 210-567-4598; Fax: 210-567-6960; E-mail:
chandraseka@uthscsa.edu.
2 The abbreviations used are: IL, interleukin; ChIP, chromatin immunoprecipi-
tation; IBMX, 3-isobutyl-l-methylxanthine; IL-18R, interleukin-18 receptor;
NFAT, nuclear factor of activated T cells; PAI-1, type-1 plasminogen-activa-
tor inhibitor; siRNA, small interferingRNA; nt, nucleotide(s); ELISA, enzyme-
linked immunosorbent assay; RT, reverse transcription; qPCR, quantitative
PCR; MAPK, mitogen-activated protein kinase; ERK, extracellular regulated
kinase; MEK, MAPK/ERK kinase; C/EBP, CAAT/enhancer-binding protein;
ANOVA, analysis of variance; GKLF, gut-enriched Kruppel-like factor; JNK,
c-Jun N-terminal kinase.
THE JOURNAL OF BIOLOGICAL CHEMISTRY VOL. 283, NO. 7, pp. 4200–4209, February 15, 2008
Printed in the U.S.A.
4200 JOURNAL OF BIOLOGICAL CHEMISTRY VOLUME 283•NUMBER 7•FEBRUARY 15, 2008
 at Y
O
N
SEI U
N
IV
ERSITY
 on O
ctober 29, 2014
http://w
w
w
.jbc.org/
D
ow
nloaded from
 
with the apoE/ single knockout mice (22). Together, these
reports indicate that IL-18 exerts both pro-inflammatory and
pro-atherogenic effects.
Because circulating levels of adiponectin show an inverse
relationship with IL-18 in several pathological conditions (11–
15, 23, 24), we investigated whether this relationship is coinci-
dental or has a causal basis. Here we demonstrate for the first
time that IL-18 suppresses adiponectin expression by adipo-
cytes via a pathway featuring ERK1/2-dependent NFATc4
phosphorylation and activation. These data suggest that the
relationship between IL-18 and adiponectin plasma levels has a
direct causal component, and that targeting IL-18 is a poten-
tially effective strategy for enhancing adiponectin expression
and attenuating disease progression.
EXPERIMENTAL PROCEDURES
Materials—Recombinantmouse IL-18 (B002–5), IL-18-neu-
tralizing antibodies (IL-18Ab; D048–3), anti-mouse IL-18R
antibody (AF856), anti-mouse IL-18R antibody (AF199), nor-
mal goat IgG1 (AB-108-C), recombinant mouse IL-18BPd/Fc
chimera (#122-BP), and Fc were purchased from R&D Systems
(Minneapolis, MN). Donkey anti-goat fluorescein isothiocya-
nate-conjugated antibodies (Cat. no. 705-095-147) were from
Jackson ImmunoResearch Laboratories (West Grove, PA). The
NFAT luciferase reporter plasmid (pNFAT-Luc) was obtained
from Panomics (Freemont, CA). Antibodies to NFATc2 (sc-
7296) andNFATc4 (sc-13036)were purchased fromSantaCruz
Biotechnology, Inc. (Santa Cruz, CA). Antibodies to -actin
(A300–491A) and nucleolin (A300–711A) were purchased
from Bethyl Laboratories, Inc. (Montgomery, TX). Antibodies
to phospho-Ser676 NFATc4, generated using synthetic phos-
pho-peptide (Lys-Arg-Ser(P)-Pro-Thr-Gln-Ser-Phe-Arg-Phe-
Leu-Pro-Val-Ile-Cys) encoding human NFATc4 and conju-
gated to ovalbumin have been described previously (generously
provided by Chi-Wing Chow, Dept. of Molecular Pharmacol-
ogy, Albert Einstein College of Medicine, Bronx, NY) (25).
Antibodies to total (#9102) and phosphoERK1/2 (#9101S)were
purchased from Cell Signaling Technology, Inc. (Beverly, MA).
MEK Inhibitor U0126 (Promega), ERK1/2 inhibitor (PD98059;
10 M in Me2SO for 1 h) and Me2SO were from EMD Bio-
sciences (San Diego, CA). Insulin, IBMX, dexamethasone, and
all other chemicals were purchased from Sigma-Aldrich.
Cell Culture—3T3-L1 preadipocytes (#CL-173) were pur-
chased from ATCC (Manassas, VA). Cells were cultured in
Dulbecco’s modified Eagle’s medium containing high glucose
and supplemented with 50 units/ml penicillin, 50 g/ml strep-
tomycin, 100 mM minimal essential medium sodium pyruvate,
and 10% fetal calf serum. All tissue culture reagents were pur-
chased from Invitrogen. When confluent (day 0), cells were
differentiated into adipocytes by supplementing the medium
with 5 g/ml insulin, 1 M dexamethasone, and 0.5 mM
3-isobutyl-1-methylxanthine (IBMX). After 48 h, the medium
was replaced with Dulbecco’s modified Eagle’s medium plus
10% fetal calf serum supplemented with 5g/ml insulin. Forty-
eight hours later, medium was replaced with fresh Dulbecco’s
modified Eagle’s medium plus 10% fetal calf serum. Five days
later, the fully differentiated adipocytes were used in the exper-
iments. In addition to pharmacological inhibitors, ERK1/2
expression was targeted by ERK1 and ERK2 siRNA duplexes.
Treatment with pharmacological inhibitors, transfections,
knockdown, or adenoviral infection did not affect cell viability
(trypan blue dye exclusion).
IL-18 Receptor Expression-RT-PCR and Flow Cytometry—
IL-18 receptor expression was analyzed by RT-PCR using
DNA-free total RNA isolated from adipocytes and receptor-
specific primers: IL-18R (GenBankTM accession NM_008365,
195 nt): sense, 5-GTG CAC AGG AAT GAA ACA GC-3
(bases 519–537) and antisense, 5-ATT TAA GGT CCA ATT
GCG ACG A-3 (bases 692–713); IL-18R (GenBankTM
NM_010553, 241 nt): sense, 5-GGA GTG GGA AAT GTC
AGT AT-3 (bases 1321–1340), and antisense, 5-CCG TGC
CGA GAA GGA TGT AT-3 (bases 1561–1535). Surface
expression of IL-18R and - were measured by flow cytom-
etry. In brief, fully differentiated 3T3-L1 cells were gently
trypsinized, washed twice in phosphate-buffered saline, fixed in
2% paraformaldehyde for 10 min, and resuspended in phos-
phate-buffered saline containing antibodies to IL-18R,
IL-18R, or normal goat IgG at 1:100 dilution for 1 h at 37 °C.
Cells were washed in phosphate-buffered saline, and incubated
for an additional 1 h at 37 °C with donkey anti-goat IgG conju-
gated to fluorescein isothiocyanate (1:100). The cell suspension
was then washed twice in phosphate-buffered saline and ana-
lyzed by fluorescence-activated cell sorting.
Plasminogen Activator Inhibitor-1 Production—Adipocytes
were treatedwith IL-18 (10 ng/ml) for 48 h. PAI-1 levels in culture
supernatants were quantified by ELISA (Mouse PAI-1 ELISA kit,
Molecular Innovations, Inc., Southfield, MI). Specificity of IL-18
was verified by treating cells with neutralizing IL-18 antibodies or
IL-18BP/Fc chimera (10 g/ml) for 1 h prior to IL-18 treatment.
Normal rat IgG1 and Fc served as controls.
Adiponectin Expression—Adiponectin mRNA expression
was quantified by real-time PCR. DNA-free total RNAwas pre-
pared using the RNAqueous-4PCR kit (Ambion). RNAquality
was assessed by capillary electrophoresis using theAgilent 2100
Bioanalyzer (Agilent Technologies, Palo Alto, CA). All RNA
samples used for quantitative PCR had RNA integrity numbers
of9.1 (scale 1–10), as assigned by default parameters of the
Expert 2100 Bioanalyzer software package (v2.02). A total of 2
l of cDNA was used, and amplification was performed in
duplicate in an ABI PRISM 7900 Sequence Detector (PE
Applied Biosystems, Foster City, CA) using the following
primer sets for adiponectin: sense primer, 5-AAG GAC AAG
GCC GTT CTC T-3; antisense primer, 5-CGC ACG ATT
TCC CTC TCA GCT G-3. The results were quantified by the
Ct method using -actin (sense, 5-CA GGG TGT GAG
TTGGGGAATG-3; antisense, 5-CGCACGATTTCCCTC
TCA GCT G-3) as internal standard. Effects of IL-18 on adi-
ponectin gene transcription were determined using nuclear
run-on assays (26), and on adiponectin mRNA stability by acti-
nomycin D pulse (26), followed by RT-qPCR.
Adiponectin secretion was quantified by an ELISA (Mouse
adiponectin ELISA kit, Cat. no. EZMADP-60K, Millipore, Bil-
lerica, MA) that detects all forms of adiponectin except the
globular form (Technical data sheet, Millipore).
Adiponectin Promoter-Reporter Assays—The region of the
mouse adiponectin gene promoter spanning1138 to30 bp
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in the pGL3-Basic vector (p1138-Luc) has been described pre-
viously (27). The deletion construct p312-Luc was generated
using the following primers: sense, 5-ggtaccGGTACCGAG-
GATAATTTTCATTGCAC-3; antisense, 5-ctcgagTCGTCA-
GATCCACTGACAATCGT-3. Mutation of the NFAT bind-
ing site (from AAACTTATGGGAAAGGGAG to AAACTTA-
TCTTAAAGGGAG; sense, 5-AGG ACA AAC TTA TCT
TAAAGGGAGGTCTCCTGAC-3) in p1138-Luc construct
was generated by site-directed mutagenesis (28). Adipocytes
were transfected with 3 g of the promoter-reporter vectors
and 100 ng of the control Renilla luciferase vector pRL-TK
(Promega) using Lipofectamine (19, 26). After incubation for
the indicated timeperiods, the cellswere harvested for the dual-
luciferase assay. Data were normalized by dividing firefly lucif-
erase activity with that of the corresponding Renilla luciferase.
All plasmids were purified using EndoFree Plasmid Maxi kit
(Qiagen), and transfections did not result in cell death.
Western Blotting, Enzyme Activity, and Immunocomplex
Kinase Assays—NFAT levels were determined in whole cell
homogenates by immunoblotting using isotype-specific anti-
bodies (19, 26). Similarly, phospho-NFATc4 levels in cytoplas-
mic and nuclear extracts were determined using phospho-spe-
cific (Ser676) antibodies. -Actin and nucleolin served as
markers of purity of cytoplasmic and nuclear protein extracts,
respectively, and to verify equal loading of proteins. ERK1/2
activation was determined by immunoblotting using activa-
tion-specific antibodies and immune-complex kinase assays
(ERK1/2, p44/42 MAPK Assay Kit, Cell Signaling Technology,
Inc.) (29).
Reporter and Chromatin Immunoprecipitation Assays—
NFAT activation was analyzed by reporter assays using adeno-
viral transduction of NFAT reporter vector (Ad-NFAT-Luc, 50
multiplicity of infection, catalog no. 1665, Vector Biolabs, Phil-
adelphia, PA). Ad-MCS-Luc (50 multiplicity of infection; cata-
log no. 1680, Vector Biolabs) served as a control. Ad--gal (50
multiplicity of infection; catalog no. 1080, Vector Biolabs)
served as an internal control. Twenty-four hours after infec-
tion, cells were treated with IL-18 (10 ng/ml) for an additional
12 h. Firefly luciferase activity in cell extracts was determined as
previously described (19, 26, 29).-Galactosidase activity in cell
extracts was determined using a Luminescence -Galactosid-
ase Detection Kit II (BD Biosciences), and the results are
expressed in relative light units as a ratio of firefly luciferase to
-galactosidase activity.
In vivo DNA binding of NFATc4 to the adiponectin pro-
moter was confirmed by ChIP assays (29). Adipocytes were
treated with IL-18 (10 ng/ml) for 1 h. The ChIP assay was car-
ried out as previously described (29) using the Chromatin
Immunoprecipitation Assay kit (catalog no. 17-295, Upstate
Biotechnology Inc., Lake Placid, NY). Immunocomplexes were
prepared using anti-p-NFATc4(Ser676) antibody. The superna-
tant of an immunoprecipitation reaction carried out in the
absence of antibody was used as the total input DNA control.
PCR was carried out on 1 l of a 1:100 dilution of each sample
using adiponectin promoter-specific primers: sense (432 to
413), 5-GCT TCA CAT TTA GTT ACA AA-3 and anti-
sense (292 to 273), 5-ATA ATT CAG CAT GTT TCT
GA-3, that would amplify a 160-bp fragment, followed by anal-
ysis on 2% agarose gels. Primers predicted to amplify a 200-bp
fragment of exon 3 of the adiponectin gene (sense, 5-GTC
TCC ACGACT CTT ACA TG-3 and antisense, 5-ACA TTC
ATA CAC TCA GCC TG-3) were used as the PCR control.
siRNA—GKLF (sc-35479), C/EBP (sc-29862), NFATc2 (sc-
36056), NFATc4 (sc-38116), ERK1 (sc-29308), and ERK2 (sc-
35336) siRNAwere purchased from Santa Cruz Biotechnology,
Inc. Non-targeting siRNA (5-UUC UCC GAA CGU GUC
ACG Utt-3; no. 1022076, Qiagen, Valencia, CA) served as a
negative control. Cells were transfected with 100 nM (GKLF,
C/EBP, NFATc2, or NFATc4) or 25 nM (ERK1 and ERK2)
siRNAusingOligofectamineTM reagent (Invitrogen). 48 h later,
knockdown of corresponding proteins was confirmed byWest-
ern blotting using whole cell homogenates.
Cell Death Detection ELISA—Adipocytes were treated with
IL-18 at the indicated concentration for up to 3 days. Cells were
harvested and analyzed for mono- and oligonucleosomes in the
cytoplasmic fractionof cell lysates byELISA (CellDeathDetection
ELISAPLUS kit, Roche Applied Science, Indianapolis, IN) (30).
Esculetin (6,7-dihydroxy-2H-1-benzopyran-2-one, 400 M for
48 h, Sigma-Aldrich), a coumarin derivative and a known inducer
of adipocyte death (31), was used as a positive control.
Statistical Analysis—Results are expressed as means  S.E.
For statistical analysis we used ANOVA followed by an appro-
priate post hocmultiple comparison test (Tukey method). Each
experiment was performed at least three times, and data were
considered statistically significant at p 0.05.
RESULTS
IL-18 Does Not Induce Cell Death in Adipocytes—Treatment
with insulin, IBMX, and dexamethasone induces the differen-
tiation of 3T3-L1 preadipocytes into fully differentiated adipo-
cytes as characterized by the intracellular accumulation of lipid
droplets (Fig. 1A, arrows). In all subsequent experiments, fully
FIGURE 1. IL-18 does not affect adipocyte viability. A, fully differentiated
3T3-L1 adipocytes. 3T3-L1 preadipocytes were treatedwith a combination of
insulin, dexamethasone, and IBMX as described under “Experimental Proce-
dures.” Arrows indicate lipid droplets in differentiated adipocytes. B, RT-PCR
showing the expression of the ligand-binding and the signal-transducing
subunits of the IL-18 receptor by adipocytes under basal condition. C, flow
cytometry showing themembraneexpressionofand subunits of the IL-18
receptor by adipocytes under basal conditions. D, IL-18 does not induce adi-
pocyte death. Adipocytes were treated with IL-18 for 72 h. Esculetin (400 M
for 48 h) served as a positive control. *, p 0.001 versus untreated by ANOVA.
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differentiated 3T3-L1 preadipocytes will be termed adipocytes.
We investigated whether adipocytes express subunits  and 
of the IL-18 receptor. RT-PCR of DNA-free total RNA and
receptor-specific primers show that, under basal conditions,
adipocytes express both the ligand-binding  and the signal-
transducing  subunits of IL-18 receptor (Fig. 1B). Flow cyto-
metry confirmedmembrane expression of IL-18 receptors  and
 (Fig. 1C). Because IL-18 can exert pro-apoptotic effects in
some cell types, we next investigated whether IL-18 affects adi-
pocyte survival. Adipocytes were treated with IL-18 at the indi-
cated concentrations for 72 h. Cell death was analyzed by quan-
tifying mono- and oligonucleosomal fragmented DNA in the
cytoplasmic extracts. Even at the maximum concentration of
100 ng/ml, IL-18 had no detectable
effect on adipocyte viability (Fig.
1D). However, esculetin, a known
inducer of adipocyte apoptotic cell
death (31), induced significant cell
death (p  0.001). These results
indicate that (i) adipocytes express
the ligand binding  and the signal
transducing  subunits of IL-18
receptor and (ii) IL-18 does not
induce adipocyte death under the
conditions used in our experiments
(Fig. 1).
IL-18 Suppresses Adiponectin,
but Not PAI-1, Expression in
Adipocytes—Since an inverse rela-
tionship between systemic IL-18
and adiponectin levels has been
reported for various chronic patho-
logical conditions (11–15, 23, 24),
we investigated whether this rela-
tionship may have a causal basis.
Addition of IL-18 to the adipocytes
resulted in a dose-dependent sup-
pression of adiponectin secretion,
with significant suppression de-
tected at 10 ng/ml (Fig. 2A). No fur-
ther suppression of adiponectin
secretion was observed at IL-18
concentrations of up to100 ng/ml.
The suppressive effect of IL-18 was
blocked by IL-18 neutralizing anti-
bodies and by an IL-18BP:Fc chi-
mera (Fig. 2B), demonstrating spec-
ificity for IL-18. To show that the
IL-18-induced suppression of adi-
ponectin secretion was the result of
a selective effect of IL-18 on the
adipocytes, rather than from a glo-
bal inhibition of all secretory
activity, we also quantified the
levels of PAI-1 in the adipocyte
culture supernatants. In contrast
to its suppressive effects on adi-
ponectin secretion, IL-18 stimu-
lated PAI-1 secretion from the adipocytes (Fig. 2C), indicat-
ing the suppression of adiponectin by IL-18 to be a selective
effect. Because adiponectin suppresses PAI-1 expression
(32), our results suggest that the effect of IL-18 on PAI-1
expression is either direct or due to reduced adiponectin
expression following IL-18 treatment.
We next investigated the effects of IL-18 on adiponectin
mRNA expression. IL-18 suppressed the net levels of adiponec-
tin transcripts in the adipocytes, a response that was also
blocked by the IL-18 neutralizing antibodies and IL-18BP:Fc
chimera (Fig. 2D). To determine whether the decreasedmRNA
levels were due to reduced transcription or to post-transcrip-
tional events, we studied the effects of IL-18 on adiponectin
FIGURE 2. IL-18 suppresses adiponectin expression. A, IL-18 suppresses adiponectin secretion. Adipocytes
were treatedwith IL-18 for 24h.Adiponectin levels in culture supernatantswerequantifiedbyELISA. *,p0.01
versus untreated. B, IL-18 neutralizing antibodies and IL-18BP:Fc inhibit IL-18-mediated suppression in adi-
ponectin secretion. Adipocyteswere treatedwith IL-18 antibodies or IL-18BP:Fc (10g/ml for 1 h) prior to IL-18
addition (10 ng/ml for 24 h). Adiponectin levels were quantified as in A. *, p 0.01 versus untreated, †, p 0.05
versus IL-18. C, IL-18 stimulates PAI-1 secretion. Culture supernatants of adipocytes treated as in B were ana-
lyzed for PAI-1 levels by ELISA.p0.001 versusuntreated, †,p0.01 versus IL-18.D, IL-18 suppresses adiponec-
tinmRNAexpression.Adipocyteswere treatedwith IL-18neutralizingantibodiesor IL-18BP:Fcprior to IL-18 (10
ng/ml for 24 h). Adiponectin mRNA expression was quantified by RT-qPCR. *, p 0.01 versus untreated, †, p
0.05 versus IL-18 by ANOVA. E, IL-18 does not alter adiponectin mRNA half-life. Adiponectin mRNA half-life in
IL-18-treated and control adipocytes was evaluated by actinomycin D pulse followed by RT-qPCR at the time
points indicated (n 6). F, IL-18 suppresses adiponectin gene transcription. Adiponectin gene transcription
following IL-18 exposure was evaluated by nuclear run-on assays (n 3). Glyceraldehyde-3-phosphate dehy-
drogenase (GAPDH) was used as an internal control and TOPO 2.1 served as a vector control.
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transcription by nuclear run-on assay and on mRNA stability
using an actinomycin D pulse. Adipocytes were treated with
IL-18 for 6 h, followed by an actinomycin D pulse for up to 6 h.
Adiponectin mRNA was quantified by RT-qPCR. As shown in
Fig. 2E, the calculated half-lives of adiponectin mRNA in the
untreated controls and IL-18-treated cells were essentially
identical, suggestive of similar degradation rates. In contrast,
nuclear run-on assays revealed suppressed adiponectin gene
transcription following IL-18 treatment (Fig. 2F). Thus
together, these results indicate that (i) IL-18 selectively
inhibits adiponectin expression, (ii) reduced adiponectin
expression is not due to cell death (Fig. 1C), and (iii) IL-18-
mediated suppression of adiponectin expression is due to
reduced gene transcription (Fig. 2).
IL-18 Suppresses Adiponectin Promoter-Reporter Activity via
NFATc4—We next investigated the effect of IL-18 on adi-
ponectin promoter activity. Adipocytes were transiently trans-
fected with the full-length adiponectin promoter-reporter con-
struct (p-1138-Luc) and treated with IL-18. IL-18 markedly
attenuated adiponectin promoter activity, with a significant
reduction of firefly luciferase activity (p  0.001) compared
with controls. Previous studies have identified a repressor
region (472 to 313) in the mouse adiponectin gene pro-
moter that contains a number of responsive elements (28). To
determine whether this region is also responsible for the sup-
pressive effect of IL-18, we generated a deletion construct
(p312-Luc), which lacks this region, and tested it in transfection
assays. In the unstimulated cells, the activity of this construct
was significantly higher than the larger construct containing
the repressor region (p 0.05 versus p1138-Luc) (Fig. 3B). Fur-
thermore, treatment with IL-18 failed to inhibit the reporter
activity of this construct, suggesting that the repressor region
between 472 and 312 bp may also mediate responsiveness
to IL-18. The repressor region of the mouse adiponectin pro-
moter contains binding sites for NFAT (363 to 344), gut-
enriched Kruppel-like factor (GKLF, 409 to 395), and
C/EBP (462 to451), among others.
To determine the relative importance of each of these tran-
scription factors in IL-18-mediated suppression of adiponectin
promoter, we targeted the expression of each of these transcrip-
tion factors using siRNA. In the case of NFAT, previous studies
have shown that the expression of the NFATc2 and NFATc4
isoforms is increased during the differentiation of 3T3-L1
fibroblasts into adipocytes, with higher levels of NFATc4 than
NFATc2 (25). However, no change was reported in NFATc1
and NFATc3 levels during differentiation. Therefore, we tar-
FIGURE 3. IL-18 suppresses adiponectin transcription in NFATc4-dependent manner. A, IL-18 suppresses adiponectin promoter-reporter activity.
Adipocytes transiently transfectedwith full-length adiponectin promoter were treatedwith IL-18 (10 ng/ml for 12 h). Co-transfectionwith pRL-TK vector
served as a control for transfection efficiency. *, p  0.001 versus IL-18-treated pGL3-Basic, †, p  0.01 versus p1138-Luc alone. B, deletion construct
(p312-Luc) lacking C/EBP, GKLF, andNFAT binding sites failed to respond to IL-18-mediated suppression. *, p 0.001 versus pGL3-Basic, †, p 0.05 versus
p1138/30. C, knockdown of NFATc4, but not C/EBP, GKLF, or NFATc2, reverses IL-18-mediated suppression of adiponectin promoter-reporter
activity. *, p 0.001 versus pGL3-Basic, †, p 0.001 versus p1138-Luc alone, §, p 0.01 versus IL-18-treated p1138-Luc. D, knockdown of C/EBP, GKLF,
NFATc2, and NFATc4 were confirmed by Western blotting. -Tubulin served as a control. E, knockdown of NFATc4 reverses IL-18-mediated suppression
of adiponectin mRNA expression. Adipocytes were transfected with NFATc4 siRNA and were treated with IL-18 48 h post-transfection. Adiponectin
mRNA expression was analyzed by RT-qPCR. Actin served as a control. *, p  0.001 versus untreated, †, p  0.01 versus IL-18 by ANOVA.
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geted NFATc2 andNFATc4 expression by specific siRNA. Our
results demonstrate that knockdown of NFATc4, but not
NFATc2, C/EBP, or GKLF, reversed IL-18-mediated suppres-
sion of adiponectin promoter-reporter activity (Fig. 3C).
Knockdown of C/EBP, GKLF, NFATc4, and NFATc2 was
confirmed byWestern blotting (Fig. 3D). Furthermore, knock-
down of NFATc4 reversed IL-18-mediated suppression of adi-
ponectin mRNA expression (Fig. 3E). Together, these results
indicate that IL-18 suppresses adiponectin expression via
NFATc4 (Fig. 3).
IL-18 Induces NFAT Activation, Nuclear Translocation, and
DNA Binding—Next we investigated whether IL-18 induces
NFAT activation as assessed by the adenoviral transduction
with a reporter vector containing four repeats of NFATbinding
sites. Ad-MCS-Luc served as a control. IL-18 significantly stim-
ulated NFAT-dependent reporter gene activity (Fig. 4A), and
this was blocked by IL-18 neutralizing antibodies. We next
investigated if IL-18 increases nuclear NFATc4 levels. The
results in Fig. 4B show that treatment with IL-18 did indeed
increase NFATc4 levels in the nucleus of the adipocytes.
NFATc4 is present in the cytoplasm in an inactive state due to
phosphorylation at Ser168/170. Because dephosphorylation at
Ser169/170 results in its activation and nuclear translocation (33,
34), we investigated whether IL-18 alters pNFATc4 (Ser168/170)
levels in cytoplasm. Surprisingly, we found that levels of phos-
pho-NFATc4(Ser168/170) in the cytoplasm were not altered fol-
lowing IL-18 treatment (Fig. 4C). Although phosphorylation at
Ser168/170 keeps NFATc4 in an inactive state and localized to
the cytoplasm, it has been recently demonstrated that phospho-
rylation at Ser676 promotes its activation and nuclear translo-
cation (25). Therefore, we investigated whether IL-18 induces
NFATc4 phosphorylation at Ser676. Using phospho-specific
antibodies and Western blotting, we observed that IL-18, but
not neutralized IL-18, induced phosphorylation of NFATc4 at
Ser676 (Fig. 4D) resulting in its nuclear translocation (Fig. 4E).
Furthermore, using ChIP assays, we observed that treatment
with IL-18 also induced the binding of NFATc4(Ser676) to the
adiponectin promoter (Fig. 4F). Together, these results indicate
that (i) IL-18 induces NFAT activation, nuclear translocation,
and binding to the adiponectin promoter and (ii) IL-18-medi-
atedNFATc4 activation, andDNAbinding is not dependent on
dephosphorylation at Ser168/170, but rather on phosphorylation
at Ser676 (Fig. 4).
IL-18 Induces NFATc4 Phosphorylation and Adiponectin
Expression via ERK—Various MAPKs have been shown to reg-
ulate the phosphorylation status of NFAT transcription factors
(33–35). Therefore, we investigated whether IL-18-induced
NFATc4 phosphorylation at Ser676 ismediated byMAPKs.Our
results show that, although inhibition of p38 MAPK by SB, or
JNKby SP, failed tomodulate (Fig. 5A), inhibition of ERK by PD
markedly attenuated IL-18-mediated NFATc4 phosphoryla-
tion at Ser676 (Fig. 5B). In addition, knockdown of ERK1/2 also
inhibited IL-18-mediated NFATc4 phosphorylation at Ser676
(Fig. 5C); knockdown of ERK1/2 was confirmed by Western
blotting (Fig. 5D).Our results also show that IL-18 inducedERK
phosphorylation (Fig. 5E) and kinase activity (Fig. 5F), and pre-
treatment with the MEK inhibitor U0126 or the ERK inhibitor
PD attenuated ERK phosphorylation (Fig. 5G) and kinase activ-
ity (Fig. 5H).Moreover, PD and ERK1/2 knockdown, but not SB
or SP, reversed IL-18-mediated suppression of adiponectin
promoter-reporter activity (Fig. 6A), mRNA expression (Fig.
6B), and secretion (Fig. 6C). Together, these results indicate
that IL-18 suppresses adiponectin expression via ERK-depend-
ent NFATc4 phosphorylation at Ser676 (Figs. 5 and 6).
DISCUSSION
Here we demonstrate for the first time that IL-18 sup-
presses adiponectin expression in adipocytes via a novel
signal transduction pathway involving ERK-dependent
NFATc4 phosphorylation. These results suggest that the
inverse relationship observed between IL-18 and adiponec-
tin in various chronic inflammatory conditions may not be
coincidental, but rather, has a causal component. Therefore,
targeting IL-18 expression may enhance adiponectin expres-
sion and blunt disease progression.
FIGURE 4. IL-18 induces NFATc4 activation. A, IL-18 induces NFAT-depend-
ent reportergeneactivity. Adipocyteswere infectedwithadenovirus express-
ing NFAT reporter vector for 24 h. Cells were left untreated or treated with
IL-18 neutralizing antibodies (10 g/ml for 1 h) prior to IL-18 addition (10
ng/ml for 12 h). Ad-MCS-Luc served as a control. Ad--gal served as an inter-
nal control. Firefly and -galactosidase activities in cleared cell lysates were
analyzed as described under “Experimental Procedures.” *, p 0.001 versus
untreated, p 0.05 versus IL-18-treatedAd-NFAT-Luc. B, treatmentwith IL-18
increases nuclear total NFATc4 levels, but fails to alter cytoplasmic phospho-
NFATc4 (Ser168/170) levels (C). However, IL-18 increases cytoplasmic (D) and
nuclear (E) phospho-NFATc4 (Ser676) levels. -Actin and nucleolin served as
controls. These experimentswereperformedat least six times, and represent-
ative experiments are shown. F, IL-18 increases NFATc4(Ser676) DNA binding
to adiponectin promoter in vivo. Adipocytes were treated with IL-18 (10
ng/ml for 2 h), and NFATc4(Ser676) binding to DNA was analyzed by ChIP
assays using adiponectin gene-specific primers andphospho-NFATc4(Ser676)
antibodies.
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During the past 20 years, there has been a steady increase in
obesity in the U.S. and other developing countries as a result of
increased caloric intake and sedentary lifestyle. In addition, the
number of individuals with morbid obesity is increasing due to
the accumulation of excessive amounts of fat in both adipose
(subcutaneous and visceral) and non-adipose tissue. Of note,
obesity is associated with insulin resistance, type II diabetes,
coronary artery disease, hypertension, dyslipidemia, metabolic
syndrome, and increased mortality. Although adipose tissue
serves as an energy reserve, it also acts as an endocrine gland
secreting various adipokines, such as leptin, resistin, and adi-
ponectin, and these mediators in turn affect energy metabo-
lism. Adiponectin is secreted exclusively by adipose tissue (1, 2,
36), but paradoxically, obesity is associated with decreased cir-
culating adiponectin levels (3, 4). However, expression levels of
other adipokines such as leptin, tumor necrosis factor-, and
PAI are not altered, and in fact their levels are increased during
obesity (5, 6), suggesting that obesity is selectively associated
with decreased adiponectin levels. Plasma adiponectin declines
during early phases of obesity and persist at these low levels.
Adiponectin is a 	28-kDa protein consisting of 244 amino
acids (37). It has an N-terminal signal sequence, a variable
domain, a collagen-like (tail) domain, and aC-terminal globular
(head) domain (36). Its expression is regulated at transcrip-
tional, translational, and post-translational levels. Post-transla-
tional modification by glycosylation and hydroxylation results
in a low molecular weight trimer, a middle molecular weight
hexamer, and a high molecular weight multimer (38). A small
globular fragment of adiponectin-globular adiponectin can also
be detected in the circulation, but at lower levels (39). Although
all of these isoforms are detectable in plasma, their differential
significance in the pathophysiology of cardiovascular and met-
abolic diseases is not completely known. In both animals and
humans, lower levels of circulating high molecular weight, but
not other isoforms, correlate with the onset and progression of
metabolic abnormalities, coronary artery disenso, and type II
diabetes (37). In addition, weight loss following diet, liposuc-
tion, or gastric bypass is also shown to be predominantly due to
the highmolecular weight isoform (40, 41). The ELISAmethod
used in the present study does not differentiate among the high,
middle, and low molecular weight isoforms of adiponectin and
does not detect the globular form.Therefore, based on the stud-
FIGURE 5. IL-18 suppresses adiponectin expression via ERK1/2-depen-
denet NFATc4 phosphorylation. A, IL-18-induced NFATc4 (Ser676) phos-
phorylation is not dependent onp38MAPKand JNK.Adipocyteswere treated
with the p38 MAPK inhibitor SB or the JNK inhibitor SP for 1 h prior to IL-18
addition (10 ng/ml for 1 h). Phospho-NFATc4(Ser676) levels were analyzed in
cleared cell lysates byWestern blotting. Tubulin served as an internal control.
A representative of six experiments is shown. B and C, IL-18 induces
NFATc4(Ser676) phosphorylation via ERK1/2. Adipocytes were treated with
the ERK1/2 inhibitor PD (B) or ERK1 and 2 siRNA (C) prior to IL-18 addition.
Phospho-NFATc4(Ser676) levels were analyzed as in A. D, knockdown of
ERK1/2 was confirmed by Western blotting. Tubulin served as an internal
control. E, IL-18 induces ERK activation. Adipocytes treated with IL-18 for var-
ious timeperiodswere analyzed for total and phospho-ERK levels byWestern
blotting. F, IL-18 induces ERK kinase activity. Adipocytes treated as in E were
analyzed for ERKactivationby immunocomplexkinaseassays.GandH, PD inhib-
its IL-18-mediatedERKactivation.AdipocytesweretreatedwithPDfor1hprior to
IL-18addition. ERKactivationwasanalyzedbyWesternblottingusingactivation-
specific antibodies (G) and immunocomplex kinase assays (H).
FIGURE6. Inhibitionof ERK, butnotp38MAPKor JNK, reverses IL-18-mediated suppressionof adiponectin expression.Adipocyteswere transfected (A)
or not (B andC) with adiponectin promoter-reporter, treated for 1 (SB, SP, or PD) or 48 h (ERK1 and2 siRNAor control siRNA) followedby IL-18 for 12 h (A) or 24 h
(B and C). Adiponectin mRNA expression was analyzed by RT-qPCR (B) and its secretion by ELISA (C). A: *, p  0.001 versus pGL3-Basic, †, p  0.01 versus
p1138-Luc, §, p 0.001 versus IL-18 alone or IL-18Me2SO; B and C: *, p 0.001 versus untreated,
†, p 0.01 versus IL-18 by ANOVA.
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ies by others (37, 40, 41), we hypothesize that the observed
decrease in adiponectin following IL-18 treatment was due
mainly to a reduction of the high molecular weight isoform. In
the future, we will test this possibility in vitro in adipocytes and
in vivo in relevantmousemodelswhen the appropriate reagents
become available.
Adiponectin exerts both anti-inflammatory and anti-athero-
genic effects. Kumada et al. have reported that adiponectin acts
as a modulator of the inflammatory response in the vascular
wall (42). It affects various cell types involved in atherogenesis.
For example, it inhibits monocyte-endothelial adhesion, endo-
thelial cell apoptosis, transformation ofmacrophages into foam
cells, and smoothmuscle cell proliferation (8–10). Importantly,
plasma adiponectin levels show an inverse correlationwith cor-
onary artery disease (43) and serve as a risk factor. Administra-
tion of globular adiponectin protected ob/obmice from diabe-
tes and apoE/ mice from atherosclerosis (44). In contrast,
mice deficient in adiponectin have increased neointimal prolif-
eration after injury and increased atherosclerosis (45), further
emphasizing the anti-apoptotic and anti-atherosclerotic role of
adiponectin.
While adiponectin levels decrease, systemic levels of various
pro-inflammatory cytokines increase in obesity. IL-18 is a pro-
inflammatory and proatherogenic cytokine that induces the
expression of other pro-inflammatory cytokines and adhesion
molecules (16, 17). It acts either directly or synergizes with
other cytokines to induce vascular inflammation. It localizes in
human atherosclerotic lesions (18), and circulating IL-18 levels,
which are increased in acute coronary syndromes, are predic-
tive of future cardiovascular events. A positive correlation
between serum IL-18 levels and carotid intimal-medial thick-
ening has also been demonstrated (16). Administration of IL-18
aggravates atherosclerosis in mice (46). Moreover, atherogene-
sis is reduced in IL-18-deficient apoE/mice (22), suggesting
a causal role for IL-18 in the development and progression of
atherosclerosis.
An inverse correlation has been demonstrated between sys-
temic adiponectin and IL-18 levels in various chronic inflam-
matory conditions, including obesity and coronary artery dis-
ease. Straczkowski et al. have demonstrated an association
between increased serum IL-18 concentration and hypoadi-
ponectinemia in obesity (11), whereas Giugliano et al. have
reported increased circulating IL-18 anddecreased adiponectin
in obese women that was reversed following liposuction (47).
Vilarrasa et al. have recently reported that high levels of circu-
lating IL-18 and significantly low levels of adiponectin in mor-
bidly obese patients revert toward normal with weight loss fol-
lowing gastric bypass surgery (48). However, it has not been
clear whether this inverse correlation is causal or coincidental.
Here we demonstrate that IL-18 suppresses adiponectin secre-
tion from adipocytes through the down-regulation of adi-
ponectin gene transcription and mRNA expression.
Our data demonstrate that IL-18 suppresses adiponectin
expression via ERK-dependent phosphorylation of the
NFATc4 transcription factor. The NFAT family of proteins
comprises 5 members, NFATc1-c5, whose activation is regu-
lated by calcineurin, a Ca2-dependent phosphatase (33, 34).
NFATc1 through -c4 function as transcription factors and reg-
ulate various genes. They play a role in the differentiation of
pre-adipocytes to adipocytes. Both c1 and c3 were detected at
basal conditions in preadipocytes, and their levels were not
altered during differentiation tomature adipocytes (25). In con-
trast, the low basal levels of c2 and c4 in preadipocytes showed
a dramatic increase during the differentiation process, with
high levels detected in the fully differentiated cells (25). Our
results show that knockdown of NFATc4, but not NFATc2,
significantly attenuates IL-18-mediated adiponectin gene tran-
scription and mRNA expression. Therefore, NFATc4 appears
to be the predominant member of the NFAT family that medi-
ates IL-18 signaling in adipocytes.
NFAT proteins contain both nuclear export and localization
sequences. In unstimulated cells, these sequences remain either
masked or overt based on the phosphorylation status of specific
serine residues in their regulatory domain (33, 34). Although
phosphorylation at the serine residues exposes the nuclear
export signal, dephosphorylation of the nuclear localization
signal results in translocation of the protein to the nucleus,
leading in turn to NFAT-dependent gene transcription. Phos-
phorylation at Ser168/170 retains NFATc4 in the cytoplasm, and
dephosphorylation results in its activation and nuclear translo-
cation. Our results show that, although treatment with IL-18
results in increased levels of NFATc4 in the nucleus, it does not
significantly alter p-NFATc4(Ser168/170) levels in the cyto-
plasm, suggesting that the increased nuclearNFATc4 is not due
to dephosphorylation of NFATc4 at Ser168/170, but rather to an
alternative mechanism. Further investigation revealed that
IL-18 induces NFATc4 phosphorylation at Ser676, because
treatment with IL-18 increased cytoplasmic and nuclear levels
of p-NFATc4Ser676, as well as its in vivo binding to the adi-
ponectin promoter. Our results also show that the mechanism
of IL-18 induced NFATc4 phosphorylation at Ser676 is via ERK
activation. This is the first report to demonstrate that a pro-
inflammatory cytokine, IL-18 in particular, induces NFATc4
phosphorylation at Ser676 resulting in its activation. In support
of these observations, Yang et al. have demonstrated phospho-
rylation ofNFATc4 at Ser676 in in vitro kinase assays and shown
this to enhance its transactivation potential (25).
We demonstrated that IL-18 suppresses adiponectin expres-
sion in adipocytes in vitro via ERK1/2-dependent NFATc4
phosphorylation. However, we have not yet investigated the
mechanisms involved in IL-18-mediated ERK activation in adi-
pocytes. IL-18 has been shown to be a potent inducer of ERK
activation in rheumatoid arthritis synovial fibroblasts (49), and
IL-18 mediates ERK activation via c-Src, Ras, and Raf-1. We
have previously demonstrated that IL-18 signals via MyD88,
IRAK4, IRAK1, TRAF6, and c-Src, leading toMAPK activation
(50). Studies are in progress to determine whether similar
mechanisms are operative in adipocytes.
Although obesity in humanswas shown to be associatedwith
increased IL-18 and decreased adiponectin (11), and reversed
by weight loss (47), the mechanisms involved in IL-18-medi-
ated adiponectin suppression in vivo have not been investi-
gated. It has been previously reported that systemic levels of
pro-inflammatory cytokines (e.g. tumor necrosis factor) are
increased in adiponectin null mice (51). Furthermore, adi-
ponectin has been shown to suppress cytokine expression as
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well as cytokine signaling in vitro in both immune and non-
immune cells (52). Conversely, other studies, in addition to
ours, show that cytokines inhibit adiponectin transcription and
translation (53, 54). Importantly, a single high fatmeal has been
shown to enhance systemic IL-18 and inhibit adiponectin levels
in humans (55), and a prolonged high fat diet appears to reduce
systemic adiponectin levels and increases pro-inflammatory
cytokine levels in mice (56). Thus these studies point to an
inverse relationship between cytokine and adiponectin expres-
sion that may be an important factor in the pathophysiology of
a number of metabolic diseases. Our in vitro studies described
in this report delineate one potential mechanism that may be
responsible for this inverse relationship. However, this may be
only one of a number of mechanisms operating in vivo where
the situation is likely to be far more complex. Nevertheless, in
future studies, we intend to investigate the effect of a high fat
diet on IL-18 and adiponectin expression in mice and deter-
mine if the resulting relationship is mediated via ERK1/2-de-
pendent NFATc4 phosphorylation in adipose tissue. Further-
more, these studies will include intervention by administering
IL-18 neutralizing antibodies and IL-18BP to determine the
effects of IL-18 directly.
Collectively, these data provide the first evidence that IL-18
selectively suppresses adiponectin expression via ERK-depend-
ent NFATc4 phosphorylation. Our results indicate that the
inverse correlation observed between IL-18 and adiponectin
during various pathological conditions may be causal, and not
coincidental. Therefore targeting the suppression of IL-18
expression offers a novel therapeutic strategy that may attenu-
ate disease progression via restoration of adiponectin levels.
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